FILING ANALYSIS · FRIDAY, OCTOBER 30
REGENERON PHARMACEUTICALS, INC. REGN — 8-K: Results of Operations and Financial Condition
positive
Regeneron reported strong Q3 2026 financial results, with 36% revenue growth and 70% non-GAAP EPS growth, driven by record net sales of Dupixent, EYLEA HD, and Libtayo, as well as an expanded collaboration with Sanofi worth up to $8 billion in potential milestones
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →